Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata referenced "Alterity Therapeutics," but the filing text identifies the registrant as Prana Biotechnology Limited).
Reporting Period: Financial year ended 30 June 2011.
Filing Date: 23 September 2011.
Business Overview: Prana is a development-stage biotechnology company focused on commercializing research for Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD). The company's lead asset, PBT2, is advancing into Phase II clinical trials for AD and HD. A second candidate, PBT434, is in pre-clinical development for PD.
Key Financial Metrics
| Metric | 2011 (AUD) | 2010 (AUD) |
|---|---|---|
| Revenue | $156,135 | $215,008 |
| Net Loss | $(6,431,185) | $(4,906,922) |
| Loss Per Share (Basic) | $(0.0260) | $(0.0216) |
| Cash and Cash Equivalents | $8,838,245 | $5,227,298 |
| Total Assets | $9,010,952 | $6,801,417 |
| Total Liabilities | $2,079,750 | $1,572,101 |
| Net Assets | $6,931,202 | $5,229,316 |
| Operating Cash Flow | $(4,558,415) | $(4,708,939) |
| Financing Cash Flow | $8,335,258 | $5,655,944 |
Debt and Liquidity: The company has no traditional long-term debt. Current liabilities include trade payables and a convertible promissory note/warrant arrangement with the Alzheimer's Drug Discovery Foundation (ADDF) valued at approximately $355,815. The company maintains a positive net asset position and increased cash reserves significantly through equity financing.
Material Changes vs. Prior Period
- Increased Loss: The net loss increased by approximately 31% to $6.43 million, driven primarily by a surge in Research and Development (R&D) expenses, which rose from $87,992 in 2010 to $2,329,491 in 2011.
- Revenue Decline: Revenue decreased by roughly 27%, primarily due to lower interest income ($156k vs $215k), though the company received a small donation of $6,785.
- Cash Position: Cash and cash equivalents increased by $3.6 million (69%) due to net financing proceeds of $8.3 million from share issuances and borrowings.
- Employee Count: The workforce decreased from 12 employees in 2010 to 9 employees in 2011.
Guidance, Outlook, and Risks
Clinical Outlook:
- Alzheimer's Disease (PBT2): A Phase II imaging study is expected to commence patient enrollment in November 2011, supported by a US$700,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF).
- Huntington's Disease (PBT2): A Phase II trial is being prepared for initiation in Australia before the end of 2011 and in the US in the first half of 2012.
- Parkinson's Disease (PBT434): Pre-clinical development is underway with support from a grant by The Michael J. Fox Foundation.
Capital Strategy: On 14 July 2011, the company filed a prospectus supplement to sell up to 50,000,000 ordinary shares (represented by 5,000,000 ADRs) via an "at-the-market" (ATM) facility to fund ongoing operations.
Risks and Contingencies:
- Going Concern: The company is in a development stage with a history of losses. Continued operations depend on successful capital raising and clinical trial outcomes.
- Clinical Risk: Success is contingent on the efficacy and safety of PBT2 and PBT434 in clinical trials, which carry inherent risks of failure.
- Financial Risk: Exposure to foreign currency fluctuations (USD, EUR, GBP) and the need for additional equity financing.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $8.8 million cash balance against the $4.6 million annual operating cash outflow and upcoming clinical trial costs.
- ATM Facility Utilization: Monitor the execution and pricing of the "at-the-market" share offering filed in July 2011.
- Clinical Trial Initiation: Confirm the start dates for the PBT2 Alzheimer's and Huntington's trials as scheduled for late 2011.
- Convertible Note Terms: Review the specific conversion triggers and dilution impact of the ADDF convertible promissory note and warrants.
- Patent Status: Validate the maintenance of key patents in the US, Europe, and Japan, which are critical to the company's valuation.